Teriflunomide Brands

Sanofi Genzyme's oral disease-modifying therapy (teriflunomide) for relapsing forms of multiple sclerosis, FDA approved September 12, 2012, that works by inhibiting dihydroorotate dehydrogenase (DHODH) to selectively reduce proliferating lymphocytes driving MS inflammation.